Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-PENPAL: GEN0101 plus pembrolizumab in advanced melanoma after anti‑PD‑1
jRCT2051190009Phase 2Recruiting
- Sponsor
- Ishihara Sangyo Kaisha
- Start
- Mar 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GEN0101 and pembrolizumab in melanoma, sponsored by Ishihara Sangyo Kaisha. Started Mar 2019; status: recruiting.
02
Drugs
GEN0101pembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on jRCT2051190009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051190009.